RxDoctor Payments Data

Aisha Hassan Davis

Psychiatric/Mental Health · Easton, MDNPI 1053951004

Payments from drug & device makers

$3,941in general payments, 2019–2025

Across 193 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$746
  • AbbVie$541
  • Otsuka America Pharmaceutical, Inc.$488
  • Takeda Pharmaceuticals U.S.A., Inc.$393
  • Lundbeck LLC$378
  • Indivior Inc.$289
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$3,83197%
  • Education$1103%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,941 in reported general payments places this provider in the 90th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Medicare billing

Part B allowed, 2024
$36,674
Medicare patients
44
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl24$35,263
RexultiBrexpiprazole19$32,008
SublocadeBuprenorphine12$24,972
Lurasidone Hcl38$12,685
AdderallDextroamphetamine/Amphetamine11$9,501
Duloxetine Hcl66$1,108
Trazodone Hcl128$879
Carbamazepine23$823
Hydroxyzine Hcl39$812
Bupropion XlBupropion Hcl79$756
Quetiapine Fumarate70$695
Aripiprazole37$656
Desvenlafaxine Succinate ErDesvenlafaxine Succinate21$631
Buspirone Hcl88$630
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine21$510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$541$35,26324 claims
Otsuka America Pharmaceutical, Inc.Rexulti$488$32,00819 claims
Indivior Inc.Sublocade$289$24,97212 claims
Takeda Pharmaceuticals U.S.A., Inc.Adderall$393$9,50111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,461 psychiatric/mental health providers in Maryland.

Other psychiatric/mental health in Easton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →